Profile data is unavailable for this security.
About the company
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.
- Revenue in USD (TTM)0.00
- Net income in USD-144.90m
- Incorporated--
- Employees7.00
- LocationPortage Biotech IncClarence Thomas Building, Road TownP.O. Box 4649TORTOLA VG1110Virgin Islands (British)VGB
- Phone+1 4 169291806
- Fax+1 4 169296612
- Websitehttps://portagebiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Petros Pharmaceuticals Inc | 5.82m | -13.81m | 4.40m | 21.00 | -- | 0.1586 | -- | 0.7557 | -6.35 | -6.35 | 2.74 | 4.17 | 0.1759 | 0.9524 | 2.69 | 277,256.70 | -24.66 | -32.43 | -33.75 | -68.05 | 71.98 | 62.04 | -140.20 | -201.70 | 1.74 | -- | 0.391 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Exicure Inc | 23.79m | 3.07m | 4.40m | 7.00 | 0.3982 | 0.4536 | 1.07 | 0.185 | 1.28 | 1.28 | 3.86 | 1.12 | 0.8729 | -- | -- | 1,830,000.00 | 11.25 | -41.75 | 18.34 | -55.57 | -- | -- | 12.88 | -302.07 | -- | -- | 0.00 | -- | 6,068.12 | 24.29 | 95.97 | -- | -59.57 | -- |
| Marizyme Inc | 590.91k | -79.15m | 4.43m | 13.00 | -- | -- | -- | 7.50 | -1.83 | -1.83 | 0.0139 | -0.4704 | 0.0117 | 0.9575 | 12.13 | 45,454.62 | -157.28 | -29.47 | -314.26 | -30.42 | 71.63 | 67.78 | -13,393.85 | -8,518.47 | 0.025 | -0.5887 | -- | -- | 11.04 | 18.20 | -247.03 | -- | -- | -- |
| Manuka Inc | 671.00k | -1.14m | 4.48m | 4.00 | -- | -- | -- | 6.68 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
| Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 4.50m | 25.00 | -- | -- | -- | 0.2854 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
| Zyversa Therapeutics Inc | 0.00 | -106.25m | 4.61m | 7.00 | -- | 0.2223 | -- | -- | -192.29 | -192.29 | 0.00 | 2.73 | 0.00 | -- | -- | 0.00 | -139.81 | -- | -160.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Neximmune Inc | 0.00 | -32.34m | 4.68m | 6.00 | -- | 1.04 | -- | -- | -30.86 | -30.86 | 0.00 | 3.29 | 0.00 | -- | -- | 0.00 | -125.24 | -115.07 | -178.52 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| Portage Biotech Inc | 0.00 | -144.90m | 4.69m | 7.00 | -- | 0.1465 | -- | -- | -7.96 | -7.96 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -111.60 | -19.70 | -113.27 | -26.48 | -- | -- | -- | -- | -- | -- | 0.0087 | -- | -- | -- | -520.10 | -- | -- | -- |
| Oragenics Inc | 37.65k | -20.66m | 4.75m | 5.00 | -- | 2.07 | -- | 126.15 | -8.69 | -8.69 | 0.0167 | 1.03 | 0.0038 | -- | -- | 7,530.00 | -209.44 | -97.60 | -252.98 | -106.24 | -- | -- | -54,862.55 | -36,169.75 | -- | -- | 0.0898 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Lipella Pharmaceuticals Inc | 449.62k | -4.62m | 4.78m | 5.00 | -- | 1.36 | -- | 10.64 | -0.7858 | -0.7858 | 0.0749 | 0.5194 | 0.0944 | -- | 6.16 | 89,924.00 | -96.96 | -- | -116.00 | -- | -- | -- | -1,027.31 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -13.78m | 4.79m | 5.00 | -- | 0.1747 | -- | -- | -43.56 | -43.56 | 0.00 | 26.55 | 0.00 | -- | -- | 0.00 | -17.32 | -40.33 | -18.83 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Alzamend Neuro Inc | 0.00 | -15.16m | 4.81m | 4.00 | -- | -- | -- | -- | -2.32 | -2.32 | 0.00 | -0.4146 | 0.00 | -- | -- | 0.00 | -265.85 | -- | -496.81 | -- | -- | -- | -- | -- | -- | -1,736.10 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
| China Pharma Holdings Inc | 7.01m | -3.08m | 4.83m | 231.00 | -- | 0.4647 | -- | 0.6889 | -1.06 | -1.06 | 2.07 | 0.7016 | 0.4094 | 2.18 | 15.14 | 30,351.95 | -17.98 | -29.66 | -41.91 | -55.25 | -4.01 | 6.47 | -43.91 | -73.09 | 0.332 | -8.42 | 0.3121 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| HST Global Inc | 0.00 | -146.22k | 4.93m | 1.00 | -- | -- | -- | -- | -0.0279 | -0.0279 | 0.00 | -0.1128 | 0.00 | -- | -- | -- | -17,002.33 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -26.54 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 5.05m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
Data as of Apr 25 2024. Currency figures normalised to Portage Biotech Inc's reporting currency: US Dollar USD
11.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 1.88m | 9.48% |
| Bison Wealth LLCas of 31 Dec 2023 | 213.40k | 1.08% |
| Peak6 Capital Management LLCas of 31 Dec 2023 | 51.22k | 0.26% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 29.07k | 0.15% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 21.10k | 0.11% |
| Citadel Securities LLCas of 31 Dec 2023 | 14.14k | 0.07% |
| Beacon Investment Advisory Services, Inc.as of 31 Dec 2023 | 11.40k | 0.06% |
| IEQ Capital LLCas of 31 Dec 2023 | 11.25k | 0.06% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 10.57k | 0.05% |
| Advisor Partners II LLCas of 31 Dec 2023 | 10.10k | 0.05% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
